Mohammad Hussain | SIU School of Medicine

About me

Gender

Male

Additional languages spoken

English

Education & training

Positions

Hematologist/Oncologist

Board Certifications

Internal Medicine

Medical Oncology

Hematology

Medical School

Allama Iqbal Medical College University of Punjab, Pakistan

Residency

Pinnacle Health Hospitals, Harrisburg, PA (UPMC)

Fellowship

Hematology and Oncology, Levine Cancer Institute, Charlotte, NC and Blood and Marrow Transplant, Stanford University School of Medicine

Featured Publications

^[1] Rios J. Alnoud M. Hussain MS. Ayas Z. Franco E. Mills J. Nwose J. Malbas MS. Garcia H. Tripathi MK. Benamar K. Neuropathic Pain and Related Depression in Mice: The Effect of a Terpene and a Minor Cannabinoid in Combination. 2025 Dec;13(12):.
PMID: 41463111

^[2] Hussain MZ. Naik VY. Goswami K. Jana A. Microwave-Promoted One-Pot Sustainable Synthesis of Fluorogenic Amino Acids: Late-Stage Diversification of Peptides. 2026 Jan;91(1):227-237.
PMID: 41428334

^[3] Pe T. Inthavong P. Beavon E. Muleme M. Bohora S. Roder C. Clarke NE. Richmond JA. Hussain MA. Titulaer A. Doyle J. Tai A. Athan E. Wilson A. Wade AJ. Viral hepatitis notifications: a cohort study of enhanced local follow-up in Victoria. 2025 Dec;():.
PMID: 41412589

Read All Publications

Clinical trials

Trial

Simmons Cancer Institute

KO-MEN-008: Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Active recruiting

Examining the safety, tolerability, and effectiveness of investigational drug ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia. The study drug will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.